Breaks Categories: News

FridayJun 26, 2026 9:00 am

NetworkNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Shareholders Re-elect Seven Directors at Annual Meeting

This article has been disseminated on behalf of Energy Fuels Inc. and may include paid advertising. Energy Fuels (NYSE American: UUUU) (TSX: EFR) announced the results of its annual meeting of shareholders held virtually on June 24, 2026, with all seven management nominees re-elected to the company's board of directors. Ross R. Bhappu, Michael H. Stirzaker, Barbara A. Filas, Bruce D. Hansen, Jaqueline Herrera, Benjamin Eshleman III and Dennis L. Higgs were each elected through a combination of proxy and electronic votes, with support ranging from 88.61% to 99.61% of votes cast. To view the full press release, visit https://nnw.fm/SrQkF…

Continue Reading

ThursdayJun 25, 2026 11:56 am

NetworkNewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Signs LOI to Acquire Controlling Interest in Taiwan Automation Manufacturer 

Nightfood Holdings (OTCQB: NGTF) doing business as TechForce Robotics, announced it has signed a non-binding letter of intent to acquire a 51% controlling interest in Taiwan-based Jiun Jiang Enterprise Co. Ltd., a manufacturer of semiconductor automation, advanced packaging equipment, robotics and intelligent manufacturing systems. The proposed all-stock transaction would make JJ Enterprise a majority-owned operating subsidiary, with the purchase price tied to audited financial performance under U.S. GAAP and subject to due diligence, definitive agreements and other closing conditions. The company said the acquisition would advance its strategy to build a diversified automation and advanced manufacturing platform spanning semiconductor manufacturing, AI infrastructure, pharmaceutical automation and industrial technology. Under the proposed framework, JJ…

Continue Reading

ThursdayJun 25, 2026 11:44 am

NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Multiple Sclerosis Treatment 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that it is featured in a BioMedWire editorial examining the need for new approaches to treating multiple sclerosis ("MS"), a progressive neurological disease affecting more than 2.9 million people worldwide. The editorial, titled "The Quest to Repair What Multiple Sclerosis Takes Away," highlights the limitations of current therapies, which can slow disease progression but cannot stop it completely. The editorial discusses Quantum BioPharma's development of Lucid-MS, a patented, first-in-class drug candidate designed to directly target the myelin sheath damaged by MS. The company said the potential therapy is preparing to advance…

Continue Reading

ThursdayJun 25, 2026 11:34 am

NetworkNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Engages Pinnacle Digest for Investor Marketing Campaign 

This article has been disseminated on behalf of LaFleur Minerals and may include paid advertising.  LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) has entered into a four-month content and online marketing agreement with Maximus Strategic Consulting Inc., owner and operator of PinnacleDigest.com, to provide investor relations, marketing and promotional services. Under the agreement, Maximus will produce and distribute a management interview and video featuring the company's Beacon Gold Mill and Swanson Gold Project near Val-d'Or, Québec, while also including all LaFleur Minerals news releases in PinnacleDigest.com's weekly email newsletter. The agreement runs from June 15 through Oct. 15, 2026, with LaFleur Minerals paying a one-time cash fee…

Continue Reading

ThursdayJun 25, 2026 11:11 am

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Reorganizes to Accelerate Global Commercialization Strategy

HeartBeam (NASDAQ: BEAT) announced a strategic reorganization aimed at accelerating execution, expanding global market reach and improving capital efficiency as it advances commercialization of its cardiac monitoring technology. Under the new structure, Founder and President Branislav Vajdic, Ph.D., and Executive Chairman Rich Ferrari will lead focused implementation teams designed to streamline decision-making, improve accountability and reduce costs. As part of the transition, former CEO Robert Eno will move into a consulting role. The company said its strategy centers on leveraging its patented 3D ECG platform across multiple healthcare channels while advancing development beyond arrhythmia assessment toward heart attack detection. HeartBeam also plans to expand partnerships with governments, health systems,…

Continue Reading

ThursdayJun 25, 2026 9:50 am

NetworkNewsBreaks – American Fusion Inc. (OTC: AMFN) Finalizes Testing Protocol for 5MW Texatron(TM) Fusion Engine(TM)

American Fusion (OTC: AMFN) announced it has finalized the comprehensive testing protocol for its 5MW Pre-Production Texatron(TM) Fusion Engine(TM), establishing the engineering and scientific framework that will guide validation of the company's fusion energy platform. The protocol includes plasma density and temperature measurements, neutron monitoring, spectroscopy, electrical power analysis and calibration procedures, while also providing for independent scientific observation, public release of testing video and third-party evaluation of results as the company advances toward commercial validation. The company also announced continued expansion of its intellectual property portfolio with a new U.S. patent application covering aspects of the Texatron(TM) Fusion Engine(TM)…

Continue Reading

ThursdayJun 25, 2026 9:20 am

NetworkNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Featured in BioMedWire Editorial on Emerging DNA Repair Inhibitors

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced it is featured in a BioMedWire editorial examining the growing market opportunity for next-generation DNA Damage Response ("DDR") inhibitors. The editorial, titled "Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market," highlights the continued expansion of DDR-targeted therapies beyond PARP inhibitors as the global oncology, diagnostics and precision medicine markets continue to grow. The editorial highlights Onco-Innovations' lead candidate, ONC010™, a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple repair pathways. The…

Continue Reading

ThursdayJun 25, 2026 9:10 am

NetworkNewsBreaks – Greenland Mines Ltd (NASDAQ: GRML) Completes Skaergaard Development Planning Workshop

Greenland Mines (NASDAQ: GRML) announced it has completed a three-day, multidisciplinary planning workshop for its Skaergaard Precious and Critical Metals Project in southeast Greenland, bringing together more than 15 international experts from GTK Mintec, the Geological Survey of Finland, SLR Consulting, WSP Denmark and other technical specialists. The June 22-24 sessions focused on advancing understanding of the orebody and processing pathways, planning 2026 drilling, sampling and environmental programs and establishing a roadmap toward an Initial Assessment ("IA") or Preliminary Economic Assessment ("PEA") and future development. The company said the workshop produced an integrated plan for the 2026 field campaign, a…

Continue Reading

WednesdayJun 24, 2026 1:12 pm

NetworkNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Targets Next Generation of DNA Damage Response Cancer Therapies 

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.  Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is positioning itself within the expanding DNA Damage Response (“DDR”) oncology market through development of ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple DNA repair pathways. According to an BioMedWire editorial, DDR-targeting therapies generated more than $7 billion in global sales in 2025, while the broader oncology, diagnostics and precision medicine markets are projected to approach $750 billion by 2030. The company holds exclusive worldwide rights to a portfolio of PNKP inhibitor technologies, including core compounds, delivery systems and synthetic lethality applications intended to support future development…

Continue Reading

WednesdayJun 24, 2026 10:50 am

NetworkNewsBreaks – Greenland Energy Company (NASDAQ: GLND) Advances Jameson Land Basin Toward Exploration Drilling

Robert Price, CEO of Greenland Energy Company Energy, Oil & Gas Magazine profiles CEO Robert Price as company prepares for October 2026 exploration campaign in East Greenland Greenland Energy (NASDAQ: GLND) is advancing development of the Jameson Land Basin in East Greenland, an onshore petroleum basin that CEO Robert Price described as one of the world's last largely undrilled frontier oil regions. In an interview with Energy, Oil & Gas Magazine, Price said the company holds rights to up to a 70% interest in the basin and is leveraging extensive seismic data originally collected by Atlantic Richfield Company ("ARCO") during…

Continue Reading